Respiratory Syncytial Virus Infection Pathway
New and Updated Topics and Pathways. As we head into winter and medical experts warn, once again, of a potential tripledemic of flu, COVID-19, and Respiratory Syncytial Virus (RSV), Reactome completes its coverage of these three viruses with the release of the RSV infection pathway in V87. Additional topics with new or revised pathways in this release include Cellular responses to stimuli (Cellular response to mitochondrial stress), Developmental Biology (Kidney formation and Specification of the neural plate border), Disease (Defects of platelet adhesion to exposed collagen, and Signaling by ALK in cancer), DNA Repair (Processing of DNA double-strand break ends), Hemostasis (Platelet Adhesion to exposed collagen), Metabolism (Sphingolipid metabolism), Metabolism of proteins (Mitochondrial protein degradation), Signal Transduction (Signaling by ALK and Signaling by EGFR), Transport of small molecules (Glycosphingolipid transport).
New and Updated Illustrations. New or revised Illustrations with embedded navigation features have been created for Cellular responses to stress, Developmental Biology, Diseases of hemostasis, Gastrulation, Kidney development, Metabolism of proteins, Transport of small molecules, Viral Infection Pathways and Respiratory Syncytial Virus Infection Pathway.
Thanks to our Contributors. Mazen Aljghami, Harrison Bergeron, Rui Gao, Lena Gunhaga, Xiaoyan Guo, David P Hill, Walid A Houry, Anthony Mak, Trevor Morey, Cedric Patthey, and Suzanne D Turner are our external reviewers.
Annotation Statistics. Reactome comprises 15,046 human reactions organized into 2,673 pathways involving 30,451 proteins and modified forms of proteins encoded by 11,180 different human genes, 14,594 complexes, 2,120 small molecules, and 1,046 drugs. These annotations are supported by 37,933 literature references. We have projected these reactions onto 79,040 orthologous proteins, creating 19,398 orthologous pathways in 14 non-human species. Version 87 has annotations for 4,942 protein variants (mutated proteins) and their post-translationally modified forms, derived from 357 proteins, which have contributed to the annotation of 1,796 disease-specific reactions and 723 pathways.
Tools and Data. Our services and software tools are designed for biologists, bioinformaticians, and software developers. Pathway data is available to view in our Pathway Browser, to analyze your own dataset, to download, and access programmatically through our Content and Analysis Services. The ReactomeFIViz app and ReactomeGSA package provide tools for multi-omics data analysis. The idg.reactome.org Web Portal provides a collection of web-based tools to help researchers place understudied proteins in a pathway context.
Documentation and Training. Visit our online User Guide to access documentation supporting pathway analysis of experimental data. The Developer's Zone provides detailed documentation regarding our software, tools, and web services. Training and learning materials can be found here.
About the Reactome Project. Reactome is a collaboration between groups at the Ontario Institute for Cancer Research, Oregon Health and Science University, New York University Langone Medical Center, and The EMBL - European Bioinformatics Institute. Reactome is an ELIXIR Core Data Resource as well as a Global Core Biodata Resource. Reactome annotation files and interaction data derived from Reactome are distributed under a Creative Commons Public Domain (CC0 1.0 Universal) Licence. A Creative Commons Attribution 4.0 International (CC BY 4.0) Licence applies to all software and code, database data dumps, and Pathway Illustrations (Enhanced High-Level Diagrams), Icon Library, Art and Branding Materials. A full description of the new and updated content is available on the Reactome website.
Follow us on Twitter: @reactome to get frequent updates about new and updated pathways, feature updates, and more!
For more information: If you have a question, want to provide feedback, or are interested in collaborating with us to annotate a topic, please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it..
